Cargando…

CA 125 half-life in ovarian cancer: a multivariate survival analysis.

Serum CA 125 regression after cytoreductive surgery and during the first three courses of chemotherapy was studied in 60 ovarian cancer patients and compared to known prognostic factors. Various methods reported in the literature to calculate a CA 125 half-live value were compared. Using two exponen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yedema, C. A., Kenemans, P., Voorhorst, F., Bon, G., Schijf, C., Beex, L., Verstraeten, A., Hilgers, J., Vermorken, J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1993
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968500/ https://www.ncbi.nlm.nih.gov/pubmed/8512822

Ejemplares similares

Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival
por: Williams, Kristina A., et al.
Publicado: (2014)

Multivariate Index Assay Is Superior to CA125 and HE4 Testing in Detection of Ovarian Malignancy in African-American Women
por: Dunton, Charles, et al.
Publicado: (2019)

CA125 and Ovarian Cancer: A Comprehensive Review
por: Charkhchi, Parsa, et al.
Publicado: (2020)

Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
por: Gupta, Digant, et al.
Publicado: (2009)

A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer
por: Chiang, An Jen, et al.
Publicado: (2014)

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
por: Piatek, Szymon, et al.
Publicado: (2021)

Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
por: Gupta, Digant, et al.
Publicado: (2010)

The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.
por: Fisken, J., et al.
Publicado: (1993)

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
por: Rustin, G. J., et al.
Publicado: (1996)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis
por: Wohlmuth, Christoph, et al.
Publicado: (2022)

Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients.
por: Gourevitch, M. M., et al.
Publicado: (1995)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990)

Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation
por: Menon, U, et al.
Publicado: (1999)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer
por: Song, Jin, et al.
Publicado: (2023)

Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
por: Weiland, Florian, et al.
Publicado: (2012)

High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma
por: Morales-Vásquez, Flavia, et al.
Publicado: (2016)

Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma
por: Li, Zemin, et al.
Publicado: (2020)

The Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer
por: Fayed, Salah T., et al.
Publicado: (1998)

CA125 effects on humoral immunosuppression
por: Kline, J. Bradford, et al.
Publicado: (2017)

CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer
por: Peters-Engl, C, et al.
Publicado: (1999)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
por: Barr, Chloe E., et al.
Publicado: (2023)

Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer
por: Lee, Maria, et al.
Publicado: (2016)

The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma.
por: Hawkins, R. E., et al.
Publicado: (1989)

Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative
por: Dunton, Charles J., et al.
Publicado: (2021)

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer
por: Tcherkassova, Janneta, et al.
Publicado: (2011)

TB Peritonitis Mistaken for Ovarian Carcinomatosis Based on an Elevated CA-125
por: Boss, Joseph D., et al.
Publicado: (2012)

Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis
por: Chen, Zhixiang, et al.
Publicado: (2020)

Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer
por: Tang, Ying, et al.
Publicado: (2020)

Ligand-based adoptive T cell targeting CA125 in ovarian cancer
por: Zhao, Haihong, et al.
Publicado: (2023)

Precise half-life measurements for $^{38}$Ca and $^{39}$Ca
por: Blank, B, et al.
Publicado: (2010)

The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers
por: Winarno, G. N. A., et al.
Publicado: (2020)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study
por: Bai, Huimin, et al.
Publicado: (2016)

Age, pathology and CA-125 are prognostic factors for survival in patients with brain metastases from gynaecological tumours
por: Nagtegaal, S.H.J., et al.
Publicado: (2020)

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial
por: Alexandre, J, et al.
Publicado: (2012)

Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer
por: Zwakman, Nienke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v5lqv9653u031chbqh6as44pbe